clinical trial · NCT07095465
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
Lewy Body Dementia PsychosisACP-204
brief summary
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
started
Nov 14, 2025
primary completion
Feb 1, 2029
completion
Mar 1, 2029
last updated
Sep 29, 2026
detailed description
Study Website: https://illumerastudy.com/
official title
52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol